Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144919 | 0.91 | ALDH1A1 (0.53) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4138842 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4144374 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4146568 | 0.90 | MAPT (0.64) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4144240 | 0.89 | MAPT (0.62) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4151128 | 0.89 | MAPT (0.52) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4141371 | 0.89 | ALDH1A1 (0.53) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4132531 | 0.88 | ALDH1A1 (0.53) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4147203 | 0.88 | MAPT (0.54) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4132548 | 0.87 | ALDH1A1 (0.53) | ALDH1A1GAAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | claimed |
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | TP53, BRDT, VHL | ALDH1A1 1202/4885GAA 1533/4885MEN1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.